Analysts have been eager to weigh in on the Healthcare sector with new ratings on Akero Therapeutics (AKRO – Research Report) and HealthStream (HSTM – Research Report).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akero Therapeutics (AKRO)
In a report released today, Kaveri Pohlman from Clear Street downgraded Akero Therapeutics to Hold, with a price target of $54.00. The company’s shares closed last Thursday at $54.08, close to its 52-week high of $58.40.
According to TipRanks.com, Pohlman has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akero Therapeutics with a $65.50 average price target, which is a 20.1% upside from current levels. In a report released today, Canaccord Genuity also downgraded the stock to Hold with a $54.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
HealthStream (HSTM)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on HealthStream. The company’s shares closed last Thursday at $26.51.
According to TipRanks.com, Hewitt is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HealthStream with a $28.00 average price target, representing a 2.7% upside. In a report issued on October 1, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $31.00 price target.
Read More on AKRO:
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Netflix%20on%20tv%20with%20remote%20by%20freestocks%20via%20Unsplash.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
